MedTrace Logo

AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

NCT03959514 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-09-30

No results posted yet for this study

Summary

A Phase I, randomised, single-centre, double-blind, single-dose, three period, balanced cross over study in a glucose clamp setting. The study compares the pharmacodynamic, pharmacokinetic and safety characteristics of AT247, NovoRapid® and Fiasp® in male participants with type I diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

BIOLOGICAL

NovoRapid

Rapid acting prandial insulin aspart

BIOLOGICAL

Fiasp

Fast acting prandial insulin aspart

BIOLOGICAL

AT247

Ultra rapid acting prandial insulin aspart

Sponsors & Collaborators

  • Arecor Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-12
Primary Completion
2019-07-30
Completion
2019-08-08

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03959514 on ClinicalTrials.gov